Article info

Download PDFPDF
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout
  1. Mr M K Reinders, Department of Clinical Pharmacy, Atrium Medisch Centrum Parkstad, PO Box 4446, 6401 CX Heerlen, The Netherlands; m.reinders{at}atriummc.nl
View Full Text

Citation

Reinders MK, Haagsma C, Jansen TLTA, et al
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout

Publication history

  • Accepted July 9, 2008
  • First published July 16, 2008.
Online issue publication 
May 12, 2009

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.